Uncategorized
The macro and market implications of the extraordinary CARES Act
admin | March 27, 2020
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.
The US CARES Act should have a major impact on the US economy, fundamental credit and market function. It provides unprecedented support–$349 billion in loans to small business, $150 billion to state and local governments, expanded unemployment benefits, cash payments to households and $500 billion to larger businesses. The support to larger businesses includes $450 billion that the Fed could leverage into $4.5 trillion of lending. And most of the support will flood the economy before the end of the year. Businesses and their employees, the unemployed and the capital markets should see the impact. An overview of each section, underlying details, and their macro and market implications follow.
- Keeping American Workers Paid and Employed Act: Launches programs that use the Small Business Administration to funnel $349 billion in 100% government-guaranteed, nonrecourse and largely forgivable emergency loans through banks and finance companies to small businesses and nonprofits. The act also adds $100 billion for guarantees on existing SBA-guaranteed borrowers. It should help many of these organizations survive and keep workers employed. And it should strengthen the fundamental credit of securities backed by cash flows from small business and consumers.
- Assistance for American Workers, Families and Businesses. Enhances unemployment benefits, expands eligibility, provides direct payments to most US residents, temporarily drops penalties on IRA withdrawals, encourages charity and provides an employer payroll tax credit. This directly supports households and unemployed workers. It should strengthen the fundamental credit of securities backed by consumer cash flows, including mortgage securities, auto and credit card ABS, student loans and others.
- Supporting America’s Health Care System in the Fight Against the Coronavirus. Strengthens and streamlines the ability of the US health care system to address COVID-19. Improves testing and should reduce mortality. Defers federal student loan payments for six months. Improved testing and treatment should allow more targeted use of social distancing with less drag on economic activity, restoring revenues and creditworthiness to individuals and businesses. Strengthens the credit backing student loans.
- Economic Stabilization and Assistance to Severely Distressed Sectors of the United States Economy. The main $500B program for lending to large, solvent businesses through the Treasury’s Exchange Stabilization and the Federal Reserve. The Fed should be able to leverage much of the funding up to 10 times, magnifying the impact of this appropriation. Requires borrowers to largely maintain their workforce and limits use of funds for share buybacks or executive compensation. Likely the main program for stabilizing investment grade and highly leveraged corporate borrowers and their workforce.
- Coronavirus Relief Fund. Provides $150B to states for the costs of COVID-19 public health emergencies, allocated by population with a minimum of $1.25B per state. Stabilizes US municipal finance. Should raise valuations on municipal debt securities.
- Miscellaneous Provisions. Provides $10B in support for the US Postal Service, and makes sure these bills do not trigger budget sequester or other budget enforcement actions.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
